Charles M. Farber

3.3k citations

89 papers · 2.3k indexed · 1 hit paper · h-index 24

Impact in

Genetics top 1%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 50
- Chronic Lymphocytic Leukemia Research 45
Pathology and Forensic Medicine 44
- Lymphoma Diagnosis and Treatment 43

Co-authors: Dmitry Kurouski Christopher R. Flowers Brian K. Link John D. Hainsworth Jonathan W. Friedberg Andrew D. Zelenetz James R. Cerhan Lee Sanchez
Journals: Blood (20 papers)Journal of Clinical Oncology (20 papers)British Journal of Haematology (4 papers)Frontiers in Plant Science (4 papers)Blood Advances (3 papers)
Partner nations: United States United Kingdom Belgium

In The Last Decade

Charles M. Farber

88 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study 2015 · 509 citations

Peers

Countries citing papers authored by Charles M. Farber

Since Specialization

Citations

This map shows the geographic impact of Charles M. Farber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles M. Farber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles M. Farber more than expected).

Fields of papers citing papers by Charles M. Farber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles M. Farber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles M. Farber. The network helps show where Charles M. Farber may publish in the future.

Co-authors

The 25 scholars most cited alongside Charles M. Farber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Charles M. Farber Line = papers co-authored together Charles M. Farber links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results Blood Advances ·Mazyar Shadman, John M. Burke, Jennifer L. Cultrera, Habte Yimer, Syed F. Zafar, Jamal Misleh, Subramanya S. Rao, Charles M. Farber, Aileen Cleary Cohen, Hui Yao, Adam Idoine, Qi An, Ian W. Flinn, Jeff P. Sharman	2025	4
2	A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors. Journal of Clinical Oncology ·Corey J. Langer, Brendan D. Curti, Charles M. Farber, Catherine Wheeler, David Wages, Takeshi Matsumoto, Susumu Shimoyama, Mikinaga Mori, Naoki Yamada, Ruth Ann Subach, Timothy Madden, Mary Johansen, Gary Maier, K.Y. Cheung, Marya Chaney, Matt D. Galsky	2024	2
3	Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States SHILAP Revista de lepidopterología ·Jorge J. Castillo, Edwin Kingsley, Mohit Narang, Habte Yimer, Constantin A Dasanu, Jason M. Melear, Morton Coleman, Charles M. Farber, Jonah Shulman, Emily H. Mantovani, Xiaowei Zhang, Aileen Cohen, Jane Huang	2023	3
4	Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies Blood ·Mazyar Shadman, Ian W. Flinn, Edwin Kingsley, Benjamin B. Freeman, Moshe Levy, Charles M. Farber, James D’Olimpio, Jennifer L. Cultrera, Ben Zhang, Rocco J. Crescenzo, Adam Idoine, Xiaoping Zhang, Kunthel By, Jeff P. Sharman	2023	1
5	Detection and differentiation of herbicide stresses in roses by Raman spectroscopy Frontiers in Plant Science ·Charles M. Farber, Madalyn K. Shires, J. Ueckert, Kevin Ong, Dmitry Kurouski	2023	4
6	Raman Spectroscopy and Machine Learning for Agricultural Applications: Chemometric Assessment of Spectroscopic Signatures of Plants as the Essential Step Toward Digital Farming Frontiers in Plant Science ·Charles M. Farber, Dmitry Kurouski	2022	11
7	Non-Invasive Identification of Nutrient Components in Grain Molecules ·Charles M. Farber, A. S. Islam, Endang M. Septiningsih, Michael J. Thomson, Dmitry Kurouski	2021	10
8	Non-Invasive Characterization of Single-, Double- and Triple-Viral Diseases of Wheat With a Hand-Held Raman Spectrometer Frontiers in Plant Science ·Charles M. Farber, Rebecca Bryan, Li Paetzold, C. M. Rush, Dmitry Kurouski	2020	30
9	Qualitative Analysis and Phenotyping with Raman Spectroscopy Biophysical Journal ·Mark Krimmer, Charles M. Farber, Dzmitry Kurouski	2020	1
10	Non-invasive post-mortem interval diagnostics using a hand-held Raman spectrometer Forensic Chemistry ·Alexis Baide, Charles M. Farber, Mark Krimmer, Daniel J. Wescott, Dmitry Kurouski	2020	7
11	Raman Spectroscopy Enables Non-Invasive Identification of Peanut Genotypes and Value-Added Traits Scientific Reports ·Charles M. Farber, Lee Sanchez, Stanislav Rizevsky, Alexei Ermolenkov, Bill McCutchen, John Cason, Charles E. Simpson, Mark D. Burow, Dmitry Kurouski	2020	43
12	A phase 1/2 trial of ublituximab, a novel anti‐ CD 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab British Journal of Haematology ·Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, Mazen Khalil, Daruka Mahadevan, Changchun Deng, Jennifer E. Amengual, Petros Nikolinakos, Jill Kolesar, John G. Kuhn, Peter Sportelli, Hari P. Miskin, Owen A. O’Connor	2017	61
13	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry Clinical Lymphoma Myeloma & Leukemia ·Anthony R. Mato, Chadi Nabhan, Neil E. Kay, Nicole Lamanna, Thomas J. Kipps, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Shriya Bhushan, Kristen Sullivan, E. Dawn Flick, Jeff P. Sharman	2017	24
14	Treatment of Peripheral T-Cell Lymphoma in Community Settings Clinical Lymphoma Myeloma & Leukemia ·Tatyana Feldman, Charles M. Farber, Kelly Choi, Claudio Faria, André Goy, Jacqueline Connors, Dhakshila Paramanathan, Sukhi Kaur, Eric Schultz, Michael McGuire, Stuart L. Goldberg	2017	4
15	Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial British Journal of Haematology ·Jeff P. Sharman, Charles M. Farber, Daruka Mahadevan, Marshall T. Schreeder, Heather D. Brooks, Kathryn S. Kolibaba, Suzanne Fanning, Leonard M. Klein, Daniel Greenwald, Peter Sportelli, Hari P. Miskin, Michael Weiss, John M. Burke	2016	44
16	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study Journal of Clinical Oncology ·Carla Casulo, Michelle Byrtek, Keith Dawson, Xiaolei Zhou, Charles M. Farber, Christopher R. Flowers, John D. Hainsworth, Matthew J. Maurer, James R. Cerhan, Brian K. Link, Andrew D. Zelenetz, Jonathan W. Friedberg Hit paper breakdown →	2015	509
17	Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia Supportive Care in Cancer ·Chris L. Pashos, Christopher R. Flowers, Neil E. Kay, Mark A. Weiss, Nicole Lamanna, Charles M. Farber, Susan Lerner, Jeff P. Sharman, David L. Grinblatt, Ian W. Flinn, M. Kozloff, Arlene S. Swern, Thomas K. Street, Kristen Sullivan, Gale Harding, Zeba M. Khan	2013	29
18	PCN103 Variation in Health-Related Quality of Life by Age Among Patients With Chronic Lymphocytic Leukemia Value in Health ·CL Pashos, Christopher R. Flowers, Mark A. Weiss, Nicole Lamanna, Charles M. Farber, Thomas J. Kipps, Susan Lerner, Neil E. Kay, Jeff P. Sharman, David L. Grinblatt, Ian W. Flinn, Mark Kozloff, Arlene S. Swern, Zainab Zaib Khan, Thomas K. Street, Kathleen A. Sullivan, Gale Harding, Michael J. Keating	2012	1
19	Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma Haematologica ·George Negrea, Rebecca Elstrom, Steven L. Allen, K. R., Rashid M. Abbasi, Charles M. Farber, Nick Teoh, Heather Horne, William A. Wegener, David M. Goldenberg	2010	40
20	CHOP with High Dose Cyclophosphamide Consolidation versus CHOP Alone as Initial Therapy for Advanced Stage, Indolent Non-Hodgkin's Lymphomas Leukemia & lymphoma ·Dorothy W. Pan, Jing Qin, Charles M. Farber, James P. O’Brien, Daniel A. Filippa, Carol S. Portlock	2003	8

About Charles M. Farber

Charles M. Farber is a scholar working on Genetics, Pathology and Forensic Medicine, Biophysics, Analytical Chemistry and Oncology, having authored 89 papers that have together received 2.3k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (43 papers), Spectroscopy Techniques in Biomedical and Chemical Research (12 papers), Spectroscopy and Chemometric Analyses (10 papers), Monoclonal and Polyclonal Antibodies Research (10 papers), Immunodeficiency and Autoimmune Disorders (9 papers), Viral-associated cancers and disorders (7 papers) and Insect and Pesticide Research (6 papers). The work is most often cited by research in Genetics (648 citations), Pathology and Forensic Medicine (1.1k citations), Biophysics (285 citations), Analytical Chemistry (345 citations) and Oncology (780 citations). Charles M. Farber has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include Dmitry Kurouski, Christopher R. Flowers, Brian K. Link, John D. Hainsworth, Jonathan W. Friedberg, Andrew D. Zelenetz, James R. Cerhan, Lee Sanchez, Carla Casulo and Keith Dawson. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Frontiers in Plant Science and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact